Minocycline

Generic Name
Minocycline
Brand Names
Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
Drug Type
Small Molecule
Chemical Formula
C23H27N3O7
CAS Number
10118-90-8
Unique Ingredient Identifier
FYY3R43WGO
Background

Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...

Indication

Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...

Associated Conditions
Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
Associated Therapies
-
pharmaphorum.com
·

Journey slips on FDA approval of rosacea therapy

Journey Medical's Emrosi, a new minocycline hydrochloride capsule, has received FDA approval for treating rosacea's inflammatory lesions in adults. Despite concerns over the lack of a redness reduction claim and competition from generic Oracea, Journey's CEO Claude Maraoui anticipates Emrosi's strong market position and potential $300 million annual sales, with a launch planned for Q1-Q2 2025.

FDA approves Journey Medical's rosacea treatment Emrosi

FDA approves Journey Medical's Emrosi, a 40mg minocycline hydrochloride extended-release capsule, for rosacea treatment. Developed with Dr Reddy's Laboratories, Emrosi met all co-primary and secondary endpoints in Phase III trials, outperforming placebo and Galderma's Oracea. Journey Medical aims to establish Emrosi as a new standard of care, with initial US market supply expected in H1 2025. This move challenges Galderma's dominance in the rosacea market, as highlighted by GlobalData's 2022 report.
© Copyright 2024. All Rights Reserved by MedPath